High ceftazidime-avibactam resistance among carbapenem-resistant Enterobacter species: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014

High ceftazidime-avibactam resistance among carbapenem-resistant Enterobacter species: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014–2021

Published:2024-04 Issue:4 Volume:63 Page:107105
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Wang Jiun-Ling^ORCID,Lai Chih-Cheng,Tsai Ya-Wen,Ko Wen-Chien,Hsueh Po-Ren

Funder

Pfizer Pharmaceuticals

ARC Training Centre in Lightweight Automotive Structures

National Taiwan University Hospital

Publisher

Elsevier BV

Reference20 articles.

1. Multidrug-resistant gram-negative bacteria: infection prevention and control update;Mills;Infect Dis Clin North Am,2021

2. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine);Paul;Clin Microbiol Infect,2022

3. Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli;Zeng;J Microbiol Immunol Infect,2023

4. Infectious Diseases Society of America 2023 Guidance on the treatment of antimicrobial resistant gram-negative infections;Tamma;Clin Infect Dis,2023

5. Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018;Jean;J Microbiol Immunol Infect,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients;Journal of Antimicrobial Chemotherapy;2024-08-19